Genomic Health, Inc. (NASDAQ:GHDX) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 1,386,018 shares, a decline of 24.6% from the February 15th total of 1,837,188 shares. Approximately 3.9% of the shares of the stock are short sold. Based on an average trading volume of 490,545 shares, the days-to-cover ratio is presently 2.8 days.

Shares of GHDX opened at $74.50 on Friday. The stock has a market capitalization of $2.75 billion, a P/E ratio of 70.95 and a beta of 0.97. Genomic Health has a 1-year low of $30.04 and a 1-year high of $92.18.

Genomic Health (NASDAQ:GHDX) last issued its quarterly earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.02. The firm had revenue of $104.56 million for the quarter, compared to analysts’ expectations of $101.55 million. Genomic Health had a return on equity of 16.86% and a net margin of 6.52%. Genomic Health’s revenue was up 22.0% on a year-over-year basis. During the same quarter last year, the business posted $0.05 EPS. As a group, analysts expect that Genomic Health will post 1.49 earnings per share for the current fiscal year.

A number of equities analysts recently weighed in on GHDX shares. BidaskClub raised Genomic Health from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, January 9th. CIBC started coverage on Genomic Health in a research note on Wednesday, December 19th. They issued a “market perform” rating on the stock. Oppenheimer started coverage on Genomic Health in a research note on Wednesday, December 19th. They issued a “market perform” rating on the stock. Needham & Company LLC started coverage on Genomic Health in a research note on Wednesday, January 2nd. They issued a “strong-buy” rating and a $86.00 price target on the stock. Finally, Piper Jaffray Companies lifted their price target on Genomic Health to $86.00 and gave the stock a “neutral” rating in a research note on Thursday, February 21st. Nine research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. Genomic Health presently has a consensus rating of “Hold” and a consensus target price of $63.13.

In other Genomic Health news, Director Bros. Advisors Lp Baker sold 39,259 shares of the business’s stock in a transaction dated Monday, January 14th. The shares were sold at an average price of $70.24, for a total value of $2,757,552.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Kimberly J. Popovits sold 50,000 shares of the business’s stock in a transaction dated Tuesday, December 18th. The stock was sold at an average price of $66.79, for a total transaction of $3,339,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,557,742 shares of company stock worth $114,365,174. 45.80% of the stock is owned by company insiders.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Genomic Health by 7.6% during the 4th quarter. BlackRock Inc. now owns 2,191,689 shares of the medical research company’s stock valued at $141,167,000 after acquiring an additional 154,253 shares in the last quarter. Vanguard Group Inc. grew its stake in Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after acquiring an additional 337,664 shares in the last quarter. Vanguard Group Inc grew its stake in Genomic Health by 18.6% during the 3rd quarter. Vanguard Group Inc now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after acquiring an additional 337,664 shares in the last quarter. Renaissance Technologies LLC grew its stake in Genomic Health by 26.9% during the 3rd quarter. Renaissance Technologies LLC now owns 1,783,100 shares of the medical research company’s stock valued at $125,209,000 after acquiring an additional 378,176 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in Genomic Health by 41.1% during the 4th quarter. Acadian Asset Management LLC now owns 741,268 shares of the medical research company’s stock valued at $47,741,000 after acquiring an additional 215,892 shares in the last quarter. 91.69% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and republished in violation of US & international copyright and trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2019/03/17/genomic-health-inc-ghdx-short-interest-update.html.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.

Recommended Story: What is a Futures Contract?

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.